GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (OTCPK:XVIPF) » Definitions » Return-on-Tangible-Asset

Xvivo Perfusion AB (Xvivo Perfusion AB) Return-on-Tangible-Asset : 9.22% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Xvivo Perfusion AB Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Xvivo Perfusion AB's annualized Net Income for the quarter that ended in Mar. 2024 was $8.75 Mil. Xvivo Perfusion AB's average total tangible assets for the quarter that ended in Mar. 2024 was $94.89 Mil. Therefore, Xvivo Perfusion AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 9.22%.

The historical rank and industry rank for Xvivo Perfusion AB's Return-on-Tangible-Asset or its related term are showing as below:

XVIPF' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -10.65   Med: 3.05   Max: 12.44
Current: 12.44

During the past 12 years, Xvivo Perfusion AB's highest Return-on-Tangible-Asset was 12.44%. The lowest was -10.65%. And the median was 3.05%.

XVIPF's Return-on-Tangible-Asset is ranked better than
89.19% of 860 companies
in the Medical Devices & Instruments industry
Industry Median: -2.685 vs XVIPF: 12.44

Xvivo Perfusion AB Return-on-Tangible-Asset Historical Data

The historical data trend for Xvivo Perfusion AB's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Return-on-Tangible-Asset Chart

Xvivo Perfusion AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.60 -11.10 1.37 2.93 12.05

Xvivo Perfusion AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.28 5.00 1.18 28.96 9.22

Competitive Comparison of Xvivo Perfusion AB's Return-on-Tangible-Asset

For the Medical Devices subindustry, Xvivo Perfusion AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Return-on-Tangible-Asset falls into.



Xvivo Perfusion AB Return-on-Tangible-Asset Calculation

Xvivo Perfusion AB's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=8.951/( (53.456+95.076)/ 2 )
=8.951/74.266
=12.05 %

Xvivo Perfusion AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=8.752/( (95.076+94.709)/ 2 )
=8.752/94.8925
=9.22 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Xvivo Perfusion AB  (OTCPK:XVIPF) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Xvivo Perfusion AB Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (Xvivo Perfusion AB) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.